TG Therapeutics, Inc. to Post Q3 2024 Earnings of $0.03 Per Share, B. Riley Forecasts (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) – Research analysts at B. Riley issued their Q3 2024 EPS estimates for shares of TG Therapeutics in a research note issued on Tuesday, August 6th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings per share of $0.03 for the quarter. B. Riley currently has a “Buy” rating and a $34.00 target price on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is ($0.01) per share. B. Riley also issued estimates for TG Therapeutics’ Q4 2024 earnings at $0.10 EPS, FY2024 earnings at $0.06 EPS and FY2025 earnings at $1.02 EPS.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.08. The firm had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. The business’s revenue was up 357.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.34) earnings per share.

A number of other brokerages have also recently commented on TGTX. LADENBURG THALM/SH SH raised their price objective on TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. HC Wainwright reissued a “buy” rating and issued a $49.00 price target on shares of TG Therapeutics in a research report on Tuesday, August 6th. JPMorgan Chase & Co. restated an “overweight” rating and set a $25.00 price objective on shares of TG Therapeutics in a report on Thursday, April 18th. Finally, The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.83.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock opened at $19.92 on Friday. The business has a 50-day simple moving average of $18.74 and a 200 day simple moving average of $16.65. TG Therapeutics has a one year low of $6.46 and a one year high of $23.12. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.62 and a quick ratio of 2.84. The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of 86.61 and a beta of 2.23.

Institutional Trading of TG Therapeutics

Institutional investors have recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. grew its position in TG Therapeutics by 4.1% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 102,872 shares of the biopharmaceutical company’s stock worth $1,757,000 after purchasing an additional 4,011 shares in the last quarter. Stratos Wealth Partners LTD. grew its stake in TG Therapeutics by 70.2% in the 4th quarter. Stratos Wealth Partners LTD. now owns 17,755 shares of the biopharmaceutical company’s stock valued at $303,000 after purchasing an additional 7,325 shares during the period. Valeo Financial Advisors LLC increased its position in shares of TG Therapeutics by 2.4% during the 4th quarter. Valeo Financial Advisors LLC now owns 63,300 shares of the biopharmaceutical company’s stock valued at $1,081,000 after purchasing an additional 1,500 shares during the last quarter. Strs Ohio bought a new stake in shares of TG Therapeutics during the 4th quarter worth $298,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in TG Therapeutics by 27.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 33,742 shares of the biopharmaceutical company’s stock valued at $576,000 after buying an additional 7,330 shares during the period. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.